C
엔젠바이오
354200KOSDAQ54.0 / 100
Reference Date: 2026-10-23
Financial Score24.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 53.2% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
EnzenBio is a biotech company specializing in in vitro diagnostic medical devices and services using genomic analysis, liquid biopsy, and precision diagnostics. It leverages next-generation sequencing (NGS) and bioinformatics algorithms to detect mutations in cancer and genetic diseases, offering personalized treatment solutions.
Number of Employees
56people
Average Salary
61.8M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.51Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
-33.54Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
7.51Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲152.0% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲14.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -59.2% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (3%, downtrend)
Current 721Won52-week high 2,63552-week low 661
1-month return0.0Point
1m -53.21% (strong drop)
Volume trend6.0Point
Volume surge
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral주식등의대량보유상황보고서(약식)2026-10-08